pharmaphorum

JULY 5, 2022

The new partnership will apply Mogrify’s cellular reprogramming and bioinformatics expertise to try to identify transcription factors – proteins which can turn specific genes on or off – that can be used to generate new cochlear hair cells. An estimated 1.57

In-Vivo 110

In-Vivo Bioinformatics Genetics Licensing 110

XTalks

MARCH 11, 2025

The Current State of mRNA Analytics There isnt a lot of emphasis right now being put on new method development specifically for application to multivalent mRNA vaccines. And I think this is surprising given just how many multivalent mRNA vaccines are currently in clinical development, begins Dr. Dawson.

Vaccination 65

Vaccination Vaccine Development Manufacturing 65

The Pharma Data

SEPTEMBER 1, 2020

Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Presentation Topic: Biomarkers and Bioinformatics. Author: Minton. Presentation Number: P1133.

Trials 52

Trials Clinical Trials Clinical Trials Vaccination 52